Invitae
In Brief This Week: Agilent, GeneCentric, Danaher, Invitae, Devyser, ObvioHealth, Revvity, BD, More
News items for the week of July 22, 2024.
Breast Cancer Patients With VUS Generally Not Overtreated, Real-World Data Analysis Suggests
Premium
A study drawing on germline genetic testing and claims data showed at ASCO that patients with VUS are, for the most part, managed like they have negative results.
In Brief This Week: Labcorp, Invitae, Bruker, NanoString, AstraZeneca, Cellectis, Cache DNA, More
News items for the week of May 6, 2024
Labcorp Acquiring Invitae Assets for $239M, Posts 5 Percent Rise in Q1 Revenues
The firm's revenues for Q1 were $3.18 billion, up from $3.04 billion in the same quarter last year and above the consensus Wall Street estimate of $3.12 billion.
The new Clinical Variant Modeling feature for Invitae's Generation platform showed potential in reducing variants of unknown significance in Lynch syndrome.
Mar 6, 2024
Invitae Q4 Estimated Revenues Rise 4 Percent
Feb 14, 2024
Invitae Files for Chapter 11 Bankruptcy Protection
Nov 8, 2023